Oct 09

Game Change in Houston

While this is certainly unprecedented for me, I’ve requested @eatmostlyfatali allow me to change my talk at Low Carb Houston to accommodate some Big Announcements I will soon be able to share, and he’s accepted.

In many ways, this will be unlike any talk I’ve done before or will likely do again. It will be much more like a TED talk, with a lot less slides and a lot more concise statements, summarizing my work to date and some key considerations I’d like to share.

All of which will tie in nicely to the announcements, and some very important next steps.

As they say… it’s a blessing to live in interesting times…

Sep 25

#BloodTestingDrive Sign Up for Low Carb Houston

At the upcoming conference, Low Carb Houston, on October 24-26th we’ll be hosting a blood testing drive where anyone can get their blood taken right there on site for a comprehensive set of tests:

  • C-Peptide
  • CBC With Differential/Platelet
  • Comp. Metabolic Panel (14)
  • Fatty Acids, Free (Nonesterified)
  • Ferritin, Serum
  • GGT
  • Glucagon
  • Hemoglobin A1c
  • High sensitivity C-Reactive Protein (hsCRP)
  • Insulin
  • Lipoprotein (a)
  • Nuclear Magnetic Resonance (NMR)

We’ve managed to negotiate a bulk rate price of $297 per person and the results will be analyzed at Labcorp to be returned in one to two weeks from the blood draw.

Click here to sign up: HoustonBloodDraw.com

Consider Helping Us Grow the Data Pool

While we are excited to provide these services for those who can’t easily get these tests done, a major motivator for this drive is getting more data for the benefit of the community, which is why you are given the option to provide your anonymized results to our pool, which we hope you’ll take. If you follow my work, you know how important I consider open source data for the advancement of science (this is especially important for the LC community). But, again, it’s your option either way and we appreciate the consideration.

Aug 28

Welcoming Debbie to CholesterolCode!

As CholesterolCode continues to grow, our ability to handle all the comments coming in has been a concern, but we didn’t want to miss the opportunity to answer the awesome questions you guys have either. Luckily, not too long ago, Low Carb San Diego happened…

Introducing Debbie

At Low Carb San Diego, I met Debbie – she used to be an engineer in silicon valley for 33 years, but is currently retired. She also happened to mention that she was interested in helping out Dave and I, and had the time to offer. She is passionate about learning as much as possible, and helping to get people accurate information so they can make informed decisions, and I felt that this attitude was a good fit, and her help might be a possible solution to our dilemma.

A Warm Welcome

If you haven’t guessed already, all of this is leading to introducing Debbie to the CholesterolCode readerbase! Debbie will be helping out by answering some of the comments that come in starting this week. I’ll still be replying to many of the comments that come in, as per usual, but don’t be surprised if you see Debbie around as well. This will hopefully mean, over time, even faster responses to comments especially during conferences as we continue to grow.

Aug 20

#CholesterolScience Show – With Ethan Weiss, MD

0:00 Intro and Ethan’s background

3:33 Cholesterol Skeptics and Concerned Medical Professionals – meeting in the middle.

8:20 How many patients does Ethan feel reach a decent level of knowledge about lipidology and cardiology?

10:15 Navigating the discussion on the benefits/risks of lipid changes from diet

17:15 When cholesterol is elevated for a metabolic reason alone – does it pose a greater risk?

23:00 Giving doctors the benefit of the doubt – are doctors just trying to help?

27:10 Dave’s disappointment with perceived lack of curiosity from the medicalsphere.

30:15 The difficulty in discussing possible benefits from lipoproteins and potential influence on all-cause mortality

36:50 Nuances of data collection and statin trials

Study mentioned: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial

Note from producer:
In the efficacy and safety statement for the trial mentioned it lists Merck Sharp & Dohme (manufacturers of simvastatin) as well as Hoffmann-La Roche (manufacturers of the vitamins used) as providing partial funding for the study:

The study is being funded by the UK Medical Research Council, the British Heart Foundation, Merck Sharp & Dohme (manufacturers of simvastatin[…]) and Hoffmann-La Roche (manufacturers of the vitamins[…])

doi: 10.1053/euhj.1998.1350

However in the published paper of the results it states the following:

The Clinical Trial Service Unit has a staff policy of not accepting honoraria or other payments from the pharmaceutical industry, except for the reimbursement of costs to participate in scientific meetings.

doi: 10.1016/S0140-6736(02)09327-3

44:56 If there were a trial that showed that people with high HDL, high LDL, and low triglycerides didn’t benefit from statins would [Ethan] want to know that information?

Study mentioned: Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S

52:40 Open data, machine learning, and possibilities moving forward

56:20 Non-HDL and mortality from the NHANES dataset

Twitter exchange mentioned:

58:30 Changes in ability to connect with researchers and scientists

1:00:05 What does Dave mean by risk?

1:04:10 Modifications to low carb to achieve lower LDL

1:08:55 What Dave has learned about the importance of rigorousness in self-experimentation

1:13:29 Can self-experiments have benefits applicable to people beyond the person doing them?

1:17:29 Cholesterol biosynthesis

1:18:40 Reverse causality – is there a possibility that the lipoproteins are reflecting a problem and not causing it?

Note from producer: I attempted a follow-up to see if I could find any studies looking at the impact of infusion of native mouse lipoproteins on atherosclerosis development, but I have not found any thus far.

1:24:33 Clotting, vascular injury, and engineering

1:29:55 The impact of placebo

Podcast mentioned: The Hidden Brain: The Untapped Potential of Placebos to Heal (transcript available)

1:33:23 The impact of seeing lipids change – could this impact the results of the study?

1:35:56 If it were dose dependency would all drugs that lower LDL have a likewise decrease in cardiovascular disease mortality?

1:38:46 Drug trials – ideals, replication, and funding

1:42:35 Wrap up and outro

Ethan Weiss Contact:

Twitter: @ethanjweiss

Aug 19

#CholesterolScience Show – With Nathan Owens and Nick Andre

0:00 Introductions

1:30 The Innate immune system and the adaptive immune system – what’s the difference?

3:25 The innate immune system and bacteria

8:00 How does immunity relate to atherosclerosis?

13:34 A link between atherosclerosis and diabetes/autoimmune diseases?

16:35 Absorption in the gut, and intestinal permeability

22:10 Nick and Nathan’s hypothesis

24:30 Dave’s thoughts on the hypothesis – is there anything to support or contradict the hypothesis?

28:24 The nuance of atherosclerotic plaque progression

Book mentioned: Natural History of Coronary Atherosclerosis by Constantin Velican

31:16 Multiple initiators of atherosclerosis – do they all have the same root cause?

33:00 Does atherosclerosis progression and regression come down to gateway keeping?

35:00 High frequency testing to challenge the hypothesis – Dave’s proposal

36:45 Atherosclerosis as a post-prandial phenomenon and ‘binge-ury’

40:00 Proposed testing of the hypothesis and follow-up questions regarding intestinal permeability

43:20 Learning from high carb experiments and aftereffects

49:10 The impact of the microbiome, and issues with testing in humans

51:00 Devil’s advocate – what about LDL?

1:00:00 Drugs used to prevent heart disease, lipoproteins, and how they relate to the endotoxin hypothesis

1:03:39 The disconnect in research on lipoproteins and immunity

1:08:34 How drugs relate to the endotoxin theory (cont)

1:10:04 If the drugs impact disease progression and all-cause mortality – why not take them?

1:11:32 Lean Mass Hyper-responders – do Nick and Nathan feel caution is needed to lower their LDL?

Term used: For more information on Lean Mass Hyper-responders see the page on CholesterolCode.

1:13:53 The importance of a long-term follow-up study on Lean Mass Hyper-responders

1:19:05 Outro0

Nick/Nathan’s Patreon: https://www.patreon.com/rootcausinghealth 

Twitter: https://twitter.com/rootcausing

Website: https://rootcausinghealth.com/ 

YouTube: https://www.youtube.com/channel/UCR5qmqb8ydX8rmBRwEUXJHg

Older posts «

» Newer posts